Flu Is Relentless. Crispr Might Be Able to Shut It Down (wired.com) 27
Scientists at Melbourne's Peter Doherty Institute for Infection and Immunity are working on a Crispr-based treatment -- delivered as a nasal spray or injection -- that could stop influenza infections by targeting the virus's RNA and disrupting its ability to replicate inside human cells.
The approach uses the Cas13 enzyme, a lesser-known cousin of the DNA-cutting Cas9, which can be engineered to seek out conserved regions of influenza's genetic code that are found in virtually all flu strains and are crucial to the virus's survival. The delivery mechanism would use lipid nanoparticles to ferry two molecular instructions to flu-infected cells in the respiratory tract: an mRNA that tells cells to produce Cas13 and a guide RNA that directs the enzyme to specific parts of the influenza virus's code.
Cas13 then cuts the viral RNA and effectively stops the infection at the genetic level, Sharon Lewin, the infectious diseases physician leading the project, told Wired. Early safety testing at Harvard's Wyss Institute used a "lung on a chip" model to examine whether human cells producing Cas13 could fight off flu strains including H1N1 and H3N2. The institute's founding director Donald Ingber says the studies showed no off-target effects.
The approach uses the Cas13 enzyme, a lesser-known cousin of the DNA-cutting Cas9, which can be engineered to seek out conserved regions of influenza's genetic code that are found in virtually all flu strains and are crucial to the virus's survival. The delivery mechanism would use lipid nanoparticles to ferry two molecular instructions to flu-infected cells in the respiratory tract: an mRNA that tells cells to produce Cas13 and a guide RNA that directs the enzyme to specific parts of the influenza virus's code.
Cas13 then cuts the viral RNA and effectively stops the infection at the genetic level, Sharon Lewin, the infectious diseases physician leading the project, told Wired. Early safety testing at Harvard's Wyss Institute used a "lung on a chip" model to examine whether human cells producing Cas13 could fight off flu strains including H1N1 and H3N2. The institute's founding director Donald Ingber says the studies showed no off-target effects.